title: Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
abstract: BACKGROUND
  The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles.
  
  
  METHODS
  Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18 years, diagnosed with type 2 diabetes for at least 6 months, on metformin and/or sulphonylurea, and with A(1C) ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides.
  
  
  RESULTS
  Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p < 0.0003), 7.5% greater reduction in non-HDL-C (p < 0.0001), and 7.8% greater reduction in total cholesterol (p < 0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p < 0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema.
  
  
  CONCLUSIONS
  These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.
authors.affiliation: State University of New York at Buffalo and Kaleida Health, Buffalo, NY 14209, USA. AChaudhuri@KaleidaHealth.org
authors.forename: Ajay
authors.initials: A
authors.lastname: Chaudhuri
authors.forename: Julio
authors.initials: J
authors.lastname: Rosenstock
authors.forename: Andres
authors.initials: A
authors.lastname: DiGenio
authors.forename: Luigi
authors.initials: L
authors.lastname: Meneghini
authors.forename: Priscilla
authors.initials: P
authors.lastname: Hollander
authors.forename: Janet B
authors.initials: JB
authors.lastname: McGill
authors.forename: Paresh
authors.initials: P
authors.lastname: Dandona
authors.forename: John
authors.initials: J
authors.lastname: Ilgenfritz
authors.forename: Matthew
authors.initials: M
authors.lastname: Riddle
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D008078:Cholesterol, LDL; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000069036:Insulin Glargine; D008687:Metformin; D000077205:Pioglitazone
references.citation: Diabetes Care. 2005 Jul;28(7):1547-54
references.pmid: 15983299
references.citation: Diabetes Care. 2003 Jan;26(1):16-23
references.pmid: 12502653
references.citation: Diabet Med. 2006 Jul;23(7):736-42
references.pmid: 16842477
references.citation: J Clin Invest. 1979 Nov;64(5):1309-19
references.pmid: 227931
references.citation: Diabetologia. 2006 Mar;49(3):442-51
references.pmid: 16456680
references.citation: Diabetes. 1998 May;47(5):779-87
references.pmid: 9588450
references.citation: Singapore Med J. 2009 Apr;50(4):395-9
references.pmid: 19421684
references.citation: Diabetes. 1984 Apr;33(4):333-8
references.pmid: 6323237
references.citation: Annu Rev Med. 2002;53:319-36
references.pmid: 11818477
references.citation: CMAJ. 2009 Apr 28;180(9):907-8
references.pmid: 19398731
references.citation: Circulation. 1999 Sep 7;100(10):1134-46
references.pmid: 10477542
references.citation: Diabetes Care. 2007 Jan;30(1):162-72
references.pmid: 17192355
references.citation: Diabetes Care. 2005 Aug;28(8):1916-21
references.pmid: 16043732
references.citation: J Clin Invest. 1990 Nov;86(5):1746-51
references.pmid: 2243143
references.citation: JAMA. 2008 Mar 12;299(10):1185-7
references.pmid: 18334695
references.citation: Lancet. 2005 Oct 8;366(9493):1279-89
references.pmid: 16214598
references.citation: Diabetes Care. 2006 Mar;29(3):554-9
references.pmid: 16505505
references.citation: Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S42-9
references.pmid: 12324985
references.citation: Am Heart J. 2008 Jul;156(1):112-9
references.pmid: 18585505
references.citation: Clin Chem. 1972 Jun;18(6):499-502
references.pmid: 4337382
references.citation: Arteriosclerosis. 1990 Mar-Apr;10(2):232-9
references.pmid: 2180397
references.citation: Curr Diab Rep. 2003 Oct;3(5):378-85
references.pmid: 12975027
references.citation: Circulation. 2007 Mar 27;115(12):1544-50
references.pmid: 17353438
references.citation: Arch Intern Med. 2004 Oct 25;164(19):2097-104
references.pmid: 15505122
references.citation: Circulation. 2006 May 16;113(19):2363-72
references.pmid: 16702489
references.citation: Diabetes Care. 1998 Jul;21(7):1052-7
references.pmid: 9653594
references.citation: Endocr Pract. 2010 Jul-Aug;16(4):588-99
references.pmid: 20350924
references.citation: Metabolism. 1991 Mar;40(3):275-9
references.pmid: 2000040
references.citation: Diabetes. 1993 Jun;42(6):833-42
references.pmid: 8495807
references.citation: Diabetes. 2004 Mar;53(3):513-20
references.pmid: 14988232
references.citation: Am J Cardiol. 2009 Jul 15;104(2):234-9
references.pmid: 19576353
references.citation: Arteriosclerosis. 1988 Mar-Apr;8(2):168-77
references.pmid: 3279941
references.citation: Diabetes Res Clin Pract. 2007 Aug;77(2):180-7
references.pmid: 17239474
references.citation: Diabetes Metab. 1999 Jun;25 Suppl 3:32-40
references.pmid: 10421991
references.citation: Clin Ther. 2004 May;26(5):744-54
references.pmid: 15220018
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: Am Heart J. 2008 Jan;155(1):26-32, 32.e1-6
references.pmid: 18082485
references.citation: Am J Health Syst Pharm. 2007 May 1;64(9):931-6
references.pmid: 17468147
references.citation: Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
references.pmid: 20042772